Logo

Nkarta, Inc.

NKTX

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidat… read more

Healthcare

Biotechnology

3 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$2.14

Price

+3.14%

$0.07

Market Cap

$151.637m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$9.034m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$109.239m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$1.48

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$357.668m

$448.312m

Assets

$90.644m

Liabilities

$78.542m

Debt
Debt to Assets

17.5%

-0.6x

Debt to EBITDA
Free Cash Flow

-$100.197m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases